Analysts expect Recro Pharma Inc (NASDAQ:REPH) to announce sales of $19.83 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Recro Pharma’s earnings, with the lowest sales estimate coming in at $18.70 million and the highest estimate coming in at $21.88 million. Recro Pharma reported sales of $18.28 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 8.5%. The business is expected to report its next earnings report on Wednesday, November 6th.
On average, analysts expect that Recro Pharma will report full year sales of $93.82 million for the current financial year, with estimates ranging from $92.50 million to $95.75 million. For the next year, analysts expect that the company will report sales of $102.14 million, with estimates ranging from $96.60 million to $105.32 million. Zacks’ sales averages are an average based on a survey of analysts that follow Recro Pharma.
Recro Pharma (NASDAQ:REPH) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.29. The company had revenue of $31.26 million during the quarter, compared to analysts’ expectations of $24.06 million.
A number of institutional investors and hedge funds have recently made changes to their positions in REPH. Nuveen Asset Management LLC bought a new position in Recro Pharma during the second quarter valued at $3,455,000. River & Mercantile Asset Management LLP bought a new position in Recro Pharma during the second quarter valued at $2,166,000. BlackRock Inc. increased its position in Recro Pharma by 14.9% during the second quarter. BlackRock Inc. now owns 1,292,173 shares of the specialty pharmaceutical company’s stock valued at $13,142,000 after acquiring an additional 167,346 shares during the last quarter. Wedge Capital Management L L P NC bought a new position in Recro Pharma during the second quarter valued at $1,682,000. Finally, Penn Capital Management Co. Inc. bought a new position in Recro Pharma during the second quarter valued at $1,525,000. Institutional investors own 60.56% of the company’s stock.
REPH stock opened at $12.59 on Wednesday. Recro Pharma has a one year low of $5.53 and a one year high of $13.47. The company’s fifty day moving average price is $11.68 and its 200-day moving average price is $10.18. The company has a market capitalization of $293.83 million, a PE ratio of -5.06 and a beta of -0.50.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Recommended Story: Put Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.